Anti-CD45 antibody [104-2] (Allophycocyanin) (ab25326)


  • Product nameAnti-CD45 antibody [104-2] (Allophycocyanin)
    See all CD45 primary antibodies
  • Description
    Mouse monoclonal [104-2] to CD45 (Allophycocyanin)
  • ConjugationAllophycocyanin. Ex: 645nm, Em: 660nm
  • Tested applicationsSuitable for: Flow Cyt, IPmore details
  • Species reactivity
    Reacts with: Mouse
  • Immunogen

    The details of the immunogen for this antibody are not available.

  • General notes

    This antibody is suitable for use as a marker for origin of donor and host cells.


Our Abpromise guarantee covers the use of ab25326 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use a concentration of 0.3 - 6 µg/ml. ab91364-Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
IP Use at an assay dependent concentration.


  • FunctionProtein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
  • Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
    Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain.
  • Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.
    Contains 2 fibronectin type-III domains.
    Contains 2 tyrosine-protein phosphatase domains.
  • DomainThe first PTPase domain interacts with SKAP1.
  • Post-translational
    Heavily N- and O-glycosylated.
  • Cellular localizationMembrane. Membrane raft. Colocalized with DPP4 in membrane rafts.
  • Information by UniProt
  • Database links
  • Alternative names
    • B220 antibody
    • CD 45 antibody
    • CD45 antibody
    • CD45 antigen antibody
    • CD45R antibody
    • GP180 antibody
    • L-CA antibody
    • LCA antibody
    • Leukocyte common antigen antibody
    • loc antibody
    • Ly-5 antibody
    • LY5 antibody
    • Ly5, homolog of antibody
    • Lyt-4 antibody
    • OTTHUMP00000033813 antibody
    • OTTHUMP00000033816 antibody
    • OTTHUMP00000033817 antibody
    • OTTHUMP00000038574 antibody
    • Protein tyrosine phosphatase receptor type c polypeptide antibody
    • protein tyrosine phosphatase, receptor type, C antibody
    • Ptprc antibody
    • PTPRC_HUMAN antibody
    • Receptor-type tyrosine-protein phosphatase C antibody
    • T200 antibody
    • T200 glycoprotein antibody
    • T200 leukocyte common antigen antibody
    see all

References for Anti-CD45 antibody [104-2] (Allophycocyanin) (ab25326)

This product has been referenced in:
  • Crossno JT  et al. Rosiglitazone promotes development of a novel adipocyte population from bone marrow-derived circulating progenitor cells. J Clin Invest 116:3220-8 (2006). Flow Cyt ; Mouse . Read more (PubMed: 17143331) »

See 1 Publication for this product

Product Wall

Thank you for getting back to me. I am very pleased to hear that you have been able to get this antibody working by increasing the concentration of the antibody. Please do not hesitate to get back to me if any more problems arise.